Results 11 to 20 of about 13,152 (241)

Adrenal Insufficiency due to Disseminated <i>Cryptococcus</i> in an Immunocompetent Individual. [PDF]

Case Rep Endocrinol
Primary adrenal insufficiency due to infiltrative fungal infections, such as Cryptococcus neoformans, is rare, particularly in immunocompetent patients. We present a case of an immunocompetent 61‐year‐old man who presented with bilateral adrenal enlargement and adrenal insufficiency, with a 3‐month history of generalised fatigue, weight loss and ...
Knott JA, Apostoloski Z.
europepmc   +2 more sources

A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi [PDF]

, 2013
Introduction: Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to ...
A Loyse, AT Makadzange, BJ Park, Brigitte Denis, C Bekondi, Camilla Rothe, CF Schaars, CK Muzoora, David G. Lalloo, Derek J. Sloan, DK Lewis, E Milefchik, H Mayanja-Kizza, HM Hodkinson, JC Nussbaum, Jean Chikafa, JG Hakim, JN Day, JN Jarvis, JN Jarvis, Joep J. van Oosterhout, JR Perfect, K McCarthy, KA Johansson, Laboratory Evaluation and Standards, Mavuto Mukaka, N Longley, Nicholas A. Feasey, P Mwaba, Patrick Goodson, PG Pappas, PR Kisenge, Robert J. Wilkinson, Robert S. Heyderman, RS Heyderman, SB Gordon, T Bicanic, T Bicanic, T Heikinheimo, Theresa Allain, TJ Allain, Tom Harrison   +41 more
core   +17 more sources

Successful Treatment of Refractory <i>Candida auris</i> Ventriculitis With Intraventricular Liposomal Amphotericin B. [PDF]

Clin Case Rep
ABSTRACT We report on a case of a patient in their early 60's with a history of traumatic brain injury, decompressive cranioplasty, and chronic ventriculoperitoneal (VP) shunt who presented from a nursing home with altered mental status and status epilepticus.
Vu CA, Ladd K, Ayoade FO.
europepmc   +2 more sources

New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae. [PDF]

PLoS ONE, 2015
5-Flucytosine is currently used as an antifungal drug in combination therapy, but fungal pathogens are rapidly able to develop resistance against this drug, compromising its therapeutic action. The understanding of the underlying resistance mechanisms is
Catarina Costa, Andreia Ponte, Pedro Pais, Rui Santos, Mafalda Cavalheiro, Takashi Yaguchi, Hiroji Chibana, Miguel Cacho Teixeira   +7 more
doaj   +1 more source

Epidemiological and Clinical Characteristics, Antifungal Susceptibility, and MLST-Based Genetic Analysis of Cryptococcus Isolates in Southern Taiwan in 2013–2020

Journal of Fungi, 2022
Cryptococcal meningoencephalitis (CM) is a treatable condition, but it leads to excessive morbidity and mortality. We collected 115 non-duplicated Cryptococcus clinical isolates during 2013–2020 in southern Taiwan to perform antifungal susceptibility ...
Yi-Chun Chen, Shu-Fang Kuo, Shang-Yi Lin, Yin-Shiou Lin, Chen-Hsiang Lee   +4 more
doaj   +1 more source

Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa

BMC Health Services Research, 2021
Background Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B.
Jacqui Miot, Trudy Leong, Simbarashe Takuva, Andrew Parrish, Halima Dawood   +4 more
doaj   +1 more source

Clinical Profile of 24 AIDS Patients with Cryptococcal Meningitis in the HAART Era: A Report from an Infectious Diseases Tertiary Hospital in Western Romania

Diagnostics, 2021
Management of cryptococcal infections among patients suffering from acquired immunodeficiency syndrome (AIDS) represents a medical challenge. This retrospective study aims to describe the disease management and outcomes among 24 AIDS patients who ...
Iosif Marincu, Cosmin Citu, Iulia Vidican, Felix Bratosin, Mihai Mares, Oana Suciu, Stefan Frent, Adrian Vasile Bota, Madalina Timircan, Melania Lavinia Bratu, Mirela Loredana Grigoras   +10 more
doaj   +1 more source

Flucytosine and its clinical usage

Therapeutic Advances in Infectious Disease, 2023
Flucytosine is an antifungal agent first licensed in the 1970’s. However, its clinical value has long been overlooked and its availability across the globe is limited.
L. Shamithra M. Sigera, David W. Denning
doaj   +1 more source

Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs [version 2; peer review: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2022
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create ...
Amir Shroufi, Radha Rajasingham, Bruce Larson, Joseph N. Jarvis, Rita Oladele, Charles Muthoga, Tom M. Chiller, Alexander Jordan, Nelesh P. Govender   +8 more
doaj   +1 more source

Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme

International Journal of Infectious Diseases, 2020
Background: Cryptococcal meningitis (CM) is estimated to cause 181 000 deaths annually, with the majority occurring in Sub-Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM.
Amir Shroufi, Nelesh P. Govender, Graeme Meintjes, John Black, Jeremy Nel, Mahomed-Yunus S. Moosa, Colin Menezes, Halima Dawood, Douglas Wilson, Laura Trivino Duran, Olawale Ajose, Richard A. Murphy, Thomas Harrison, Angela Loyse, Carol Ruffell, Gilles Van Cutsem   +15 more
doaj   +1 more source